In February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of my favorite stocks. Shares have jumped by more than 20,000% since then.

I believe we are about to do it again with this new AI project called Stargate

Christopher Causey net worth and biography

Christopher Causey Biography and Net Worth

Director of United Therapeutics

Mr. Causey has served as the Principal of the Causey Consortium, a professional services organization providing business strategy and marketing counsel to the healthcare industry, since 2002. Previously, Mr. Causey served as a senior marketing officer for a variety of healthcare companies. From 2001 to 2002, Mr. Causey served as Chief Marketing Officer for Definity Health Incorporated. He was also a member of the board of directors of Data Sciences International, Inc., a private company that develops wireless physiological monitoring solutions, from 2008 to 2013.

What is Christopher Causey's net worth?: The estimated net worth of Christopher Causey is at least $1.34 million as of November 1st, 2024. Causey owns 3,675 shares of United Therapeutics stock worth more than $1,338,913 as of November 20th. This net worth evaluation does not reflect any other investments that Causey may own. Learn More about Christopher Causey's net worth.
How do I contact Christopher Causey?: The corporate mailing address for Causey and other United Therapeutics executives is 1040 SPRING ST, SILVER SPRING MD, 20910. United Therapeutics can also be reached via phone at (301) 608-9292 and via email at [email protected]. Learn More on Christopher Causey's contact information.
Has Christopher Causey been buying or selling shares of United Therapeutics?: During the past quarter, Christopher Causey has sold $192,081.30 of United Therapeutics stock. Most recently, Christopher Causey sold 510 shares of the business's stock in a transaction on Friday, November 1st. The shares were sold at an average price of $376.63, for a transaction totalling $192,081.30. Following the completion of the sale, the director now directly owns 3,675 shares of the company's stock, valued at $1,384,115.25. Learn More on Christopher Causey's trading history.
Who are United Therapeutics' active insiders?: United Therapeutics' insider roster includes Michael Benkowitz (COO), Christopher Causey (Director), Raymond Dwek (Director), James Edgemond (CFO), Paul Mahon (EVP), Nilda Mesa (Director), Judy Olian (Director), Christopher Patusky (Director), Martine Rothblatt (CEO), and Louis Sullivan (Director). Learn More on United Therapeutics' active insiders.
Are insiders buying or selling shares of United Therapeutics?: During the last twelve months, insiders at the biotechnology company sold shares 79 times. They sold a total of 430,475 shares worth more than $126,938,624.54. The most recent insider tranaction occured on November, 11th when COO Michael Benkowitz sold 15,000 shares worth more than $6,109,800.00. Insiders at United Therapeutics own 11.9% of the company. Learn More about insider trades at United Therapeutics.
Information on this page was last updated on 11/11/2024.

Christopher Causey Insider Trading History at United Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
11/1/2024	Sell	510	$376.63	$192,081.30	3,675
6/13/2024	Sell	2,000	$281.53	$563,060.00	4,185
5/3/2024	Sell	2,240	$259.91	$582,198.40	4,185
12/12/2023	Sell	3,000	$249.68	$749,040.00	4,585
8/23/2022	Sell	3,500	$224.96	$787,360.00	2,835
6/27/2022	Sell	5,000	$236.79	$1,183,950.00	675
5/26/2022	Sell	5,000	$223.54	$1,117,700.00	750
8/6/2021	Sell	2,610	$210.00	$548,100.00
9/10/2018	Sell	810	$119.00	$96,390.00	1,555
9/6/2018	Sell	810	$118.00	$95,580.00	3,925
8/3/2018	Sell	580	$127.48	$73,938.40	1,605
12/7/2017	Sell	580	$134.72	$78,137.60	1,555
11/6/2017	Sell	580	$122.00	$70,760.00	2,135
10/5/2017	Sell	580	$122.00	$70,760.00
9/7/2017	Sell	580	$134.48	$77,998.40	3,295
7/6/2017	Sell	590	$132.61	$78,239.90	3,875
5/7/2015	Sell	1,500	$167.94	$251,910.00
1/2/2015	Sell	3,000	$129.25	$387,750.00
12/19/2014	Sell	1,500	$131.47	$197,205.00
11/20/2014	Sell	1,500	$127.20	$190,800.00
11/6/2014	Sell	1,500	$122.89	$184,335.00
10/2/2014	Sell	1,500	$130.65	$195,975.00
8/15/2014	Sell	1,500	$91.14	$136,710.00
7/3/2014	Sell	1,500	$91.62	$137,430.00
6/5/2014	Sell	1,500	$96.48	$144,720.00
5/1/2014	Sell	1,500	$99.30	$148,950.00	733
4/3/2014	Sell	1,500	$95.67	$143,505.00	733
3/20/2014	Sell	1,500	$96.04	$144,060.00	733
10/3/2013	Sell	1,500	$83.15	$124,725.00
9/5/2013	Sell	1,500	$73.11	$109,665.00
7/5/2013	Sell	1,500	$66.33	$99,495.00
11/26/2012	Sell	1,500	$53.33	$79,995.00
10/4/2012	Sell	1,500	$58.33	$87,495.00
9/6/2012	Sell	1,500	$55.94	$83,910.00

Christopher Causey Buying and Selling Activity at United Therapeutics

United Therapeutics Company Overview

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.

Today's Range

Now: $364.33

$359.40

$365.67

50 Day Range

MA: $363.86

$339.12

$410.00

2 Week Range

Now: $364.33

$208.62

$417.82

Volume

199,252 shs

Average Volume

398,846 shs

Market Capitalization

$16.27 billion

P/E Ratio

16.00

Dividend Yield

N/A

Beta

0.56

Bill Gates’s Next Big AI Bet: Stargate

From Brownstone Research | Ad